Development of a clinical application of Cordyceps sinensis as an antimetastatic agent utilizing the properties of its active ingredient
| Project/Area Number |
18590127
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Environmental pharmacy
|
|---|
| Research Institution | Mukogawa Women's University |
|---|
Principal Investigator |
NAKAMURA Kazuki Mukogawa Women's University, Department of Pharmacy, Professor Associate (20299093)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥2,800,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥300,000)
Fiscal Year 2007: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2006: ¥1,500,000 (Direct Cost: ¥1,500,000)
|
|---|
| Keywords | Cordyceps sinensis / cordycepin / adenosine cleaminase inhibitor / mouse B16-B16 melanoma cells / spontaneous metastatic model / survival / マウスメラノーマB16-BL6 / 高転移性がん細胞 |
|---|
| Research Abstract |
We demonstrated that cordycepin (3'-deoxyadenosine) is an active ingredient of water extracts of the fruiting bodies of cultured Cordyceps sinensis (WECS). In the first year of this project, I investigated the adjuvant effect of 2'-deoxycoformycin (DCF), an adenosine deaminase inhibitor, on the antitumor actions of WECS and cordycepin using mouse B16-BL6 melanoma and Lewis lung carcinoma cells in vitro. As a result, DCF at 5 μM reinforced the antitumor effect of WECS and cordycepin, three and three hundred-fold, respectively. DCF alone at 5 μM was wholly ineffective on the growth curves of both cell lines. In the second year of this project, we evaluated the antimetastatic effect of WECS on a spontaneous metastatic mouse model, prepared by inoculation with B16-BL6 cells into the footpad of the right hind leg. Two weeks after inoculation, the primary tumor was completely resected. DCF (0.05 mg/kg) alone or DCF plus WECS (10 mg/kg) administered intraperitoneally for one week after tumor inoculation and for one week after primary tumor resection did not prolong the survival of model mice, while WECS (10 mg/kg) alone administered intraperitoneally for the same, duration significantly prolonged mouse survival compared with that of control mice, as shown on Kaplan-Meier analysis. Survival time of control mice was less than 53 days in all cases, while three of six mice that were administered WECS (10 mg/kg) survived over 110 days. None of the mice administered WECS (10 mg/kg) showed adverse systemic effects. WECS at 3 mg/kg did not show any antimetastatic action, while WECS at 100 mg/kg significantly reduced the body weights of mice as an adverse effect. In conclusion, after removing its inactive components, WECS should be a candidate for clinical use as an antimetastatic agent.
|
Report
(3 results)
Research Products
(26 results)
